



CONCORD DRUGS LIMITED

(A PHARMACEUTICAL FORMULATIONS UNIT)

CORPORATE OFFICE : # 3-11-1/1, L.B. Nagar, Hyderabad - 500 074. A.P. India.

Tel : 091-40-24037763, 24036379

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th September 2014

Rs in Lakhs

Sl. No.	Particulars	Three months Ended	Three months Ended	Three months Ended	Half Year Ended	Half Year Ended	Year Ended
		30.09.2014	30.06.2014	30.09.2013	30.09.2014	30.09.2013	31.03.2014
		(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
1	Income from Operations :						
	(a) Net Sales / Income from Operations (Net of Excise Duty)	972.26	950.25	815.30	1,922.51	1,575.43	3,395.21
	(b) Other Operating Income	2.89	4.34	2.89	7.23	4.19	12.25
	Total Income From operations (net)	975.15	954.59	818.19	1,929.74	1,579.63	3,407.46
2	Expenses :						
	a) Operating Expenses	37.26	36.25	29.21	73.51	50.46	121.69
	b) Purchases of stock in trade	756.36	740.36	662.36	1,496.72	1,287.43	2,760.83
	c) Changes in inventories of finished goods Work-in-progress and stock-in-goods	(3.25)	(2.45)	(2.12)	(5.70)	(3.32)	(9.70)
	d) Employee benefits expense	13.21	13.23	12.25	26.44	21.49	47.40
	e) Depreciation and amortisation expense	67.04	67.04	26.28	134.08	51.53	114.25
	f) Power And Fuel	13.05	12.18	13.26	25.23	25.62	50.00
	g) Freight and Forwarding Expenses	5.32	4.21	3.96	9.53	7.20	16.79
	h) Other Expenses	13.32	12.35	20.36	25.67	41.61	85.30
	Total Expenses (a+b+c+d+e+f+g+h)	902.31	883.17	765.56	1,785.48	1,482.01	3,186.56
	Profit/(Loss) from operations before other income and Finance costs (1-2)	72.84	71.42	52.64	144.26	97.61	220.90
3	Other Income						
	Profit/(Loss) From ordinary activities before finance Cost (3+/-)4	72.84	71.42	52.64	144.26	97.61	220.90
6	Finance cost	57.84	57.07	42.25	114.91	77.86	178.05
7	Profit/(Loss) from ordinary activities before Tax (5+/-)6	15.00	14.35	10.39	29.35	19.73	42.85
8	Tax expenses						
	(a) Current Tax	2.78	2.65	-	5.43	-	-
	(b) Deferred Tax	-	-	2.00	-	4.00	8.97
	Total (a+b)	2.78	2.65	2.00	5.43	4.00	8.97
9	Net profit/(loss) for the period (7+/-)8	12.23	11.69	8.39	23.92	15.73	33.88
10	Minority interest	-	-	-	-	-	-
11	Net Profit/(Loss) after Taxes and minority interest (9+/-)10	12.23	11.69	8.39	23.92	15.73	33.88
12	Paid up Equity Share Capital (Face value of Rs.10/- per share)	724.38	724.38	724.38	724.38	724.38	724.38
13	Reserves excluding Revaluation Reserve as per balance sheet at year end	-	-	-	-	-	537.68
14	Earnings Per Share (of Rs.10/- each) (not annualised)						
	a) Basic	0.17	0.16	0.12	0.33	0.22	0.47
	b) diluted	0.17	0.16	0.12	0.33	0.22	0.47



Part II
Select Information for the Quarter and year Ended 30/09/2014

Sl. No.	Particulars	Three months Ended	Three months Ended	Three months Ended	Half Year Ended	Half Year Ended	Year Ended
		30.09.2014	30.06.2014	30.09.2013	30.09.2014	30.09.2013	31.03.2014
		(un audited)	(un audited)	(un audited)	(un audited)	(Un-Audited)	(Audited)
1	Public Shareholding						
	- Number of shares	4403250	4403250	4403250	4403250	4403250	4403250
	- Percentage of Shareholding	60.79	60.79	60.79	60.79	60.79	60.79
2	Promoter and Promoter group Shareholding(ExcludingGDRS)						
	a) Pledged/Encumbered	0	0	0	0	0	0
	- Number of Shares (000's)						
	- Percentage of shares (As a % of total shareholding of Promoter and promoter group)	0	0	0	0	0	0
	- Percentage of shares (As a % of total share Capital of the Company)	0	0	0	0	0	0
	b) Non-Encumbered						
	- Number of Shares	2840500	2840500	2840500	2840500	2840500	2840500
	- Percentage of shares (As a % of total shareholding of Promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (As a % of total share Capital of the Company)	39.21%	39.21%	39.21%	39.21%	39.21%	39.21%
	Particulars	Three Months ended 30/09/2014					
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	NIL	NIL				
	Received during the quarter	NIL	NIL				
	Disposed of during the quarter	NIL	NIL				
	Remaining unresolved at the end of the quarter	NIL	NIL				



STATEMENT OF ASSETS AND LIABILITIES	As at Sep	As at March 31,
EQUITY AND LIABILITIES		
Shareholders' Funds		
Share Capital	919.70	919.70
Reserves and Surplus	561.60	537.68
	-	-
	1,481.30	1,457.38
Non - current liabilities	-	-
Long - term borrowings	1,143.09	1,167.57
Deferred tax liabilities (Net)	38.82	38.82
Long term provisions	-	-
	1,181.90	1,206.38
Current liabilities	-	-
Short - term borrowings	567.32	563.02
Trade Payables	811.70	1,059.57
Short - term provisions	40.56	69.15
Other Current Liabilities	153.64	112.87
	1,573.23	1,804.62
Total	4,236.44	4,468.39
ASSETS	-	-
Non-current assets	-	-
Fixed assets	-	-
Net block	1,985.14	2,084.08
Capital work- in- progress	-	-
	1,985.14	2,084.08
Deferred tax assets (Net)	-	-
Long - term loans and advances	52.81	52.81
Non-current investments	-	-
Other Non- Current Assets	-	-
	52.81	52.81
Current assets	-	-
Inventories	503.03	492.35
Trade receivables	1,571.29	1,682.02
Cash and cash equivalents	3.27	10.59
Short - term loans and advances	23.15	22.15
Other current assets	97.75	124.39
	2,198.49	2,331.50
Total	4,236.44	4,468.39

- 1 The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting held on 14.11.2014
- 2 The Accounting Standard 17 relating to Segment wise reporting is not applicable as the company operates in only one segment viz. Pharmaceuticals
- 3 Previous period / year figures have been regrouped wherever necessary.

Station: HYDERABAD
Date: 14.11.2014

For Concord Drugs Limited

S. Nagi Reddy

S. Nagi Reddy
Managing director

